Waldencast plc (WALD) has acquired Novaestiq Corp., expanding Obagi Medical’s offerings beyond U.S. medical-grade skincare—a market anticipated to reach $2.2 billion by 2029.
The acquisition agreement includes cash payable at closing, ongoing royalties from Saypha® product sales, and the contingent issuance of Waldencast class A shares.
Michel Brousset, Co-Founder and CEO of Waldencast, expressed excitement about diversifying the company’s medical-grade skincare portfolio with in-office injectable procedures through Obagi Medical’s Saypha® ChIQ™ and MagIQ™ injectable HA gel lines.
